I. Rq and . Nuemen, pn!ddcnl (nomb"'!1i: 1"I.,~nl$

S. El and . V1-de-pllli, I1ue d'un OU 1'1) ,ndI!s"'IIble(l) (non

. Ollbl-'toque, 1 CI 2)déJ~ lrI"~ 1 ARA Il ou lEC (noo,'elle rontn:: ,nd,olllion du 21

.. Insuffi, I"tnal déJi . raM par ARA Il ou tEC (IIOU...,Ue c~ . re ;00) (mmbredc pall, 1111.

. Infc, Uf il 30 alUl (nombre: de pl, ID-l9ans 0 .... ," SO-~9 ans 'El ...... m 0 70 ans ~. plus

@. @bullet-ho~i<...-mls..., ) (nombre:depll ) (nomb'" de J"III, 1S .\

I. .. , P. .. Inh, and ~. , t lt _lTIfnf il I nl ~ nl pu Ru lln ! .1 A~c de n!poniC aU InoumlCnt ~t o R,;pon,c paniclJe ..... ;1=. pn!a!dcnl 151 S~uÇ d'un !III pl~, cfT.,(. ) indo!s.nble(l) 't::-I o Non ~noe du ttlI

D. ~. Iyi and . !-j-'lrii-'~-pa, 1 ''12) ARA Il <lU IEC (1IOO,'clle con,", IIIdltllllOfl du 21 ,{llII2) (1'It:II»bre de 1

. Ill, f fTcl (.' l"do lnblc1'.)otll f it il l

D. Jo, 1. D. Sl, and S. , -~ D 1O.ns '" plus Nombre dt femmes Inll m: l'lIholo\:Ir(I) auod k(s,: (nombn: de plI

. Ollt and ~. .. P<-'~-i-f, f lf .1TI~nf il I n l ~""'IHII I"~, ~nl pu Ru ila ! )1 " " L poou r "u~l{» ITI".II{~) ~ (3" AMenee de réponse .u InoumlCnt 1'fIXCd<

E. S~uç-d-'un and O. Pl~, (.) indo!s.nble(l) (no

. Di and . ~j, It:II»bre de ~II, pp.2-3

1. Insuffosluli-rfulil-déjit-ioulé, ARA Il ou 1 EC (lMX> .. dlc ~".,'" .nd>a.'100 du li fOl, 12), IIn:.Je p:!I'''DIS

L. Ha, I. Iiu-hu-lin, . Poou, D. ·~-(-ns, and S. Sl, u. prhbcr '~'l<Iu"I(.) ! 11 1 1' r .. OI dos p.lI~n,. lnh& par Ra.lln (ou Rasll 11 Cl), D lO-l9, Hl) SI 1 oU pruJltu ?? ~ffrl
URL : https://hal.archives-ouvertes.fr/hal-00201986

. Nombre, m: l'I Iholo\:Ir(I).uod h(s, : (nombn:de pI

. .. I-!-{·lq, (~ll 71 Co~ If,s ..Hka_U dIM' la ~tIo. ,rkide.'e pcMU" q~Ie(I) raIIo.(I) aloD' 11(.) kt iilITft~.ll '1 L'arriWc d. Il

I. , .. Ii, 6. A. Uln, and J. .. , _fII 1 51 _Ile OIII~ I. f t . . f t.tr.oi_ YOlTe .. ~. an"l 011 pe, I_ ... InIk~.1 ,..,... b.II"" .... bollft

R. .. Ca_m-ln-mdln_cllftllla~, Tftr(.}l o ~l~ t ,~,"~f Et ScrI~ li UM If'IIQc:;lj

L. .. Oh-bslli-!-i-011 and .. Hte, YOlTe t n l _ ;0-1_ ftf. l ' ' fi" .. .., o Ou~ leJ Y~rDn; IftUlO<lMIIH lulen, dl:j.l bon, dfrulllClfslnblel 9} A~r:<' _ _ _ d ... flreU bMIe.i ..... bIa.'fK rarrl, p.1

~. H-cr-lb and _. , I n ll ~_" ~ 51

A. "-vs, N. .. , and _. _. , tRl _ 'In-.ts

1. ~-ln-mdkll_di& and . .. ~tioii-priricir, e pooorqH4Ie(.) rallaa(" a/ ODI d(o) tü anttr{

A. M. , C. G. , G. Tt, M. , and M. J. , Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives ». Circulation, pp.825-859, 1995.

A. M. , G. Tt, C. G. , W. M. , and M. J. , Additive effects of losartan and enalapril on blood pressure and plasma active renin. » Hypertension, Feb, vol.29, issue.2, pp.634-674, 1997.

A. M. , L. A. Alexander, J. , G. A. , M. J. Sweet-c et al., « Pilot study of combined blockade of the renin-angiotensin system in essential hypertensive patients, J Hypertens, issue.8, pp.1139-1186, 2000.

A. M. , M. J. Bissery-a, . G. Than-tam, and . A. Bura-riviere, « Hormonal and hemodynamic effects of aliskiren and valsartan and their combination sodium replète normotensive individuals, Clin J Am Soc Nephrol, issue.2, 2007.

A. M. , M. J. Bissery-a, . G. Than-tam, . A. Bura-riviere, C. Vaidyanathans-s et al., « pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II?renin feedback interruption, J Am Soc Nephrol, vol.15, pp.3126-3133, 2004.

C. Jp, C. W. , and L. S. , « Effect of inhibitors of the reninangiotensin system and other antihypertensive drugs on renal outcomes : systematic review and metaanalysis » The Lancet, pp.3662026-3662059, 2005.

D. Da, « Aliskiren : the next innovation in renin-angiotensin-aldosterone blockade, » Aging Health, vol.5, pp.269-279, 2009.

F. A. , M. M. , N. J. , B. Hr, and B. M. , Angiotensin II receptor blockade: is there truly a benefit of adding an ACE inhibitor?

F. Je and C. Mp, Aliskiren: a review of its use in the management of hypertension. » : Drugs, pp.671767-92, 2007.

F. Y. , N. Y. , T. K. , M. S. , K. T. Okada-n et al., Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease : Addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker, Hypertens Res, vol.31, pp.59-67, 2008.

G. Ah and K. R. , « Renin inhibition in hypertension, J Am Coll Cardiol, vol.51, issue.5, pp.519-528, 2008.

G. X. Digeos-hasnier and . Le-heuzey-j-y, « Guide pratique de l'hypertension artérielle, pp.9-12, 2004.

H. Z. , G. C. , W. R. , B. C. , P. J. et al., The effect of combination treatment with aliskiren and blockers of the reninangiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis, BMJ, vol.344, p.42, 2012.

J. C. and H. P. Bruner-h, « Aliskiren : the first renin inhibitor for clinical treatment, Nat. Rev. Drug Discov, vol.7, pp.399-410, 2008.

J. J. , E. S. , B. Sw, L. Breton-s, and K. Dl, « Direct renin inhibition with aliskiren in obese patients with arterial hypertension, pp.1047-55, 2007.

K. Ee, M. Lm, and F. G. , Are we ready to use aliskiren in children ? » Ped Nephrol, pp.473-477, 2011.

K. H. , N. M. , N. Lg, and N. A. , « The intrarenal reninangiotensin system: from physiology to the pathobiology of hypertension and kidney disease, » Pharmacol Rev, issue.3, pp.251-87, 2007.

L. Y. Gies-j-p, « Des cibles vers l'indication thérapeutique » Dunod pharmacologie, pp.437-442, 2004.

L. D. Krzesinski-jm and . Scheen-aj, Quelle place pour une double ou triple inhibition du système rénine angiotensine aldostérone ?, Rev med Suisse, vol.4, pp.1792-1797, 2008.

M. G. De-backer-g and D. A. , Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), Journal of hypertension, vol.25, pp.1105-1187, 2007.

M. J. , C. Dj, A. M. , and G. Mf, Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats. » Circulation, pp.963072-963080, 1997.

M. A. Koenig-w, . J. Garcia-puig, S. Patel, . Uddin-a, and . Zhang, Safety and efficacy of aliskiren?amlodipine?hydrochlorothiazide triple combination in patients with moderate to severe hypertension: A 54-week, open-label Study, J

D. F. Nguyen-g, B. C. , B. L. , G. T. , and S. Jd, Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin, Journal of Clinical Investigation, vol.109, issue.11, pp.1417-1444, 2002.
DOI : 10.1172/JCI0214276

O. Ma, R. B. , and C. Dw, Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. » Science, pp.196441-196445, 1977.

O. S. , Y. Sa, P. S. , F. H. , Z. J. et al., Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial, pp.221-230, 2007.

P. Hh, P. F. , L. J. , L. Ej, and H. Nk, AVOID Study Investigators. : « Aliskiren combined with losartan in type 2 diabetes and nephropathy, N Engl J Med, issue.23, pp.3582433-3582479, 2008.

R. C. , B. P. , M. J. , and G. Jf, Additive effects of enalapril and losartan in (mREN-2)27 transgenic rats. » Hypertension, Feb, issue.2, pp.31692-31700, 1998.

. Société-française-de-médecine-vasculaire, Collège des enseignants de médecine vasculaire, Collège français de pathologie vasculaire : « Traité de médecine vasculaire, pp.579-606, 2010.

T. Ac, M. P. , N. J. Sabat-r, P. T. , I. S. Volk-hd et al., Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure : a double-blind, randomised, placebo-controlled phase IIa study, Lancet, vol.371, pp.821-827, 2008.

V. Rm, C. Cd, M. M. , and W. Rp, Aliskiren-associated acute renal failure with hyperkalemia, » Clin Nephrol, vol.98, pp.326-328, 2009.

V. A. , C. Sg, C. D. , S. B. Hsu-h, M. et al., Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide, J Hypertens, issue.1, pp.217-243, 2007.

W. Ra, M. Jj, P. M. , S. Sd, O. B. et al., Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the candesartan in heart failure : Assessment of reduction in mortality and morbidity (CHARM)-Added trial, » Eur J Heart Fail, vol.10, pp.157-63, 2008.

«. Enquête and F. , French League Against Hypertension Survey) » disponible sur : http://test.comitehta.org/wpcontent, 2010.

«. Esc, L'aliskiren au centre d'un programme complet d'études cliniques, ASPIRE HIGHER » disponible sur http://www.consensus-online, 2010.

«. Point-de-repère-n°10, Hypertension artérielle et facteur de risque associés Évolutions des traitements entre Disponible sur http, 2000.

«. Point-de-repère-n°34, Médicaments remboursables délivrés en officine : principales évolutions en Disponible sur http://www.ameli.fr/l- assurance-maladie/statistiques-et-publications/points-de-repere/n-34- medicaments-delivres-en-officine, 2009.

«. Recommandations and E. , pour la prise en charge de l'hypertension artérielle » disponible sur : http://www.sfcardio, 2007.